Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

The fda has approved a higher dose of the rivastigmine transdermal system (13.3 mg/24 hours) for the treatment of Alzheimer's disease (AD). Lower-dose patches were previously approved for mild-to-moderate disease. Rivastigamine is a reversible acetylcholinesterase inhibitor. The transdermal system is marketed by Novartis as Exelon.

Pharmacology Update